<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963232</url>
  </required_header>
  <id_info>
    <org_study_id>17054</org_study_id>
    <secondary_id>I5Q-MC-CGAX</secondary_id>
    <nct_id>NCT03963232</nct_id>
  </id_info>
  <brief_title>A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine</brief_title>
  <acronym>PERSIST</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the drug galcanezumab is safe and effective in
      participants with episodic migraine. The study will last about 53 weeks and may include up to
      12 visits.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from Baseline in the Number of Monthly Migraine Headache Days (MHDs)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in the Number of Monthly MHDs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Reduction from Baseline ≥30% in Monthly MHDs</measure>
    <time_frame>3 Months</time_frame>
    <description>Percentage of Participants with Reduction from Baseline ≥30% in Monthly MHDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Reduction from Baseline ≥50% in Monthly MHDs</measure>
    <time_frame>3 Months</time_frame>
    <description>Percentage of Participants with Reduction from Baseline ≥50% in Monthly MHDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Reduction from Baseline ≥75% in Monthly MHDs</measure>
    <time_frame>3 Months</time_frame>
    <description>Percentage of Participants with Reduction from Baseline ≥75% in Monthly MHDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Reduction from Baseline 100% in Monthly MHDs</measure>
    <time_frame>3 Months</time_frame>
    <description>Percentage of Participants with Reduction from Baseline 100% in Monthly MHDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Role Function-Restrictive Domain Score of the Migraine-Specific Quality-of-Life Questionnaire version 2.1 (MSQ v2.1)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in the Role Function-Restrictive Domain Score of the MSQ v2.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Number of Monthly MHDs Taking Medication for the Acute Treatment of Headache</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in the Number of Monthly MHDs Taking Medication for the Acute Treatment of Headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Number of Monthly Headache Days</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in the Number of Monthly Headache Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of a ≥50% Reduction from Baseline in the Number of Monthly MHDs</measure>
    <time_frame>Baseline through 3 Months</time_frame>
    <description>Time to First Occurrence of a ≥50% Reduction from Baseline in the Number of Monthly MHDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Maintain 50% Response Criteria for all 3 Months of Double-Blind Treatment</measure>
    <time_frame>3 Months</time_frame>
    <description>Percentage of Participants who Maintain 50% Response Criteria for all 3 Months of Double-Blind Treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Number of Migraine Attacks</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in Number of Migraine Attacks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Number of Migraine Headache Hours</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in Number of Migraine Headache Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Number of Headache Hours</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in Number of Headache Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Severity of Remaining Migraines</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Participant rated response options for headache severity were 1 (mild), 2 (moderate), and 3 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in the Patient Global Impression of Severity (PGI-S)</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline in the PGI-S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline on the Migraine Disability Assessment test (MIDAS) Total Score</measure>
    <time_frame>Baseline, 3 Months</time_frame>
    <description>Mean Change from Baseline on the MIDAS Total Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-Drug Antibodies</measure>
    <time_frame>3 Months</time_frame>
    <description>Percentage of Participants Developing Anti-Drug Antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</measure>
    <time_frame>3 Months</time_frame>
    <description>PK: Serum concentration of galcanezumab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">486</enrollment>
  <condition>Episodic Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Galcanezumab</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have a diagnosis of migraine as defined by International Headache
             Society (IHS) International Classification of Headache Disorders (ICHD)-3 (1.1 or 1.2)
             (ICHD-3 2018) with a history of migraine of at least 1 year prior to screening and
             migraine onset prior to age 50

          -  Prior to screening, participants must have a history of 4-14 migraine headache days
             and at least 2 migraine attacks per month on average within the past 3 months

        Exclusion Criteria:

          -  Are currently enrolled in any other clinical trial involving an investigational
             product or any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Current use or prior exposure to galcanezumab or another calcitonin gene-related
             peptide (CGRP) antibody, including those who have previously completed or withdrawn
             from this study or any other study investigating a CGRP antibody

          -  Participants who are taking, or are expected to take, therapeutic antibodies during
             the course of the study (for example, adalimumab, infliximab, trastuzumab,
             bevacizumab, etc.)

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to galcanezumab

          -  Women who are pregnant or nursing

          -  History of chronic migraine, daily persistent headache, cluster headache, medication
             overuse headache, migraine with brainstem aura, or hemiplegic migraine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu Hospital-Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>010-83198852</phone>
    </contact>
    <investigator>
      <last_name>Xiuhai Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>862389012890</phone>
    </contact>
    <investigator>
      <last_name>Jiying Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>862081048888</phone>
    </contact>
    <investigator>
      <last_name>Xiaoping Pan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guiyang Medical College</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+86 13312231575</phone>
    </contact>
    <investigator>
      <last_name>Shan Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>ShiJiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8613582131890</phone>
    </contact>
    <investigator>
      <last_name>Hebo Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First hospital affiliated to Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8613903711125</phone>
    </contact>
    <investigator>
      <last_name>Yuming Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hosp Tongji Med Col Huazhong Univ of Sci &amp; Tech</name>
      <address>
        <city>Wu Han</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>027-83662688</phone>
    </contact>
    <investigator>
      <last_name>Suiqiang Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan Union (Xiehe) Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13707114863</phone>
    </contact>
    <investigator>
      <last_name>Bo Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>073189753040</phone>
    </contact>
    <investigator>
      <last_name>Xiaosu Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8618051212086</phone>
    </contact>
    <investigator>
      <last_name>Hongru Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13861391699</phone>
    </contact>
    <investigator>
      <last_name>Ming Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Gannan Medical University</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13970102170</phone>
    </contact>
    <investigator>
      <last_name>Shanquan Zhong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pingxiang People's Hospital</name>
      <address>
        <city>Pingxiang</city>
        <state>Jiangxi</state>
        <zip>337000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13879960089</phone>
    </contact>
    <investigator>
      <last_name>Fei Yi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>No.2 Hospital Affiliated to Jilin University</name>
      <address>
        <city>Changchun City</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>043188796298</phone>
    </contact>
    <investigator>
      <last_name>Tingmin Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Huanhu Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Jinnan District</state>
        <zip>300350</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>18622271026</phone>
    </contact>
    <investigator>
      <last_name>Jialing Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Nanjing</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>862585714511</phone>
    </contact>
    <investigator>
      <last_name>Qi Wan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8613991974085</phone>
    </contact>
    <investigator>
      <last_name>Guo Gang Luo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+86 13370582096</phone>
    </contact>
    <investigator>
      <last_name>Xiaohong Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's hospital of Rizhao</name>
      <address>
        <city>Rizhao</city>
        <state>Shandong</state>
        <zip>276826</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>06333365112</phone>
    </contact>
    <investigator>
      <last_name>Shihua Sui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0086-021-38804518-22106</phone>
    </contact>
    <investigator>
      <last_name>Gang Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13501909896</phone>
    </contact>
    <investigator>
      <last_name>Xin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HuaShan Hospital Affiliated To Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8613901931232</phone>
    </contact>
    <investigator>
      <last_name>Jiahong Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>02885423550</phone>
    </contact>
    <investigator>
      <last_name>Li He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>No 1 Affiliate Hospital of Kunming Medical College</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>86138888967787</phone>
    </contact>
    <investigator>
      <last_name>Lianmei Zhong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baotou Central Hospital</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>04726955346</phone>
    </contact>
    <investigator>
      <last_name>Baojun Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13522060549</phone>
    </contact>
    <investigator>
      <last_name>Sheng Yuan Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>13612115810</phone>
    </contact>
    <investigator>
      <last_name>Li Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All India Institue of Medical Sciences (AIIMS)</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals International Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>382428</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Artemis Hospital</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Mangala Hospitals &amp; Mangala Kidney Foundation</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CHL - Apollo Hospital</name>
      <address>
        <city>Indore</city>
        <state>Madh Prad</state>
        <zip>452008</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Getwell Hospital &amp; Research Institute</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>HCG Manavata Cancer Centre</name>
      <address>
        <city>Nasik</city>
        <state>Maharashtra</state>
        <zip>422001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Deenanth Mangeshkar Hospital and Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Gobind Ballabh Pant Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University n.a. Sechenov</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>74992486300</phone>
    </contact>
    <investigator>
      <last_name>Alexey Sergeev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Headache Clinic</name>
      <address>
        <city>Moscow</city>
        <zip>121467</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>74956849244</phone>
    </contact>
    <investigator>
      <last_name>Kirill Skorobogatykh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OOO &quot;Medis&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8312152000</phone>
    </contact>
    <investigator>
      <last_name>Irina Sokolova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academician I.P. Pavlov First St-Petersburg State Medical University</name>
      <address>
        <city>St-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/migraine/CGAX#?postal=</url>
    <description>A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>prophylactic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

